Booker Harriet
Known title: CHIEF OPERATING OFFICERCIK: 0001723978
Associated companies
Transaction History
| OPCH | ▲ Buy | Option Exercise | 5,249 | $53K | 6/6/2022 | View on chart |
| OPCH | ▼ Sell | Open Market | 6,000 | $182K | 6/6/2022 | View on chart |
| OPCH | ▲ Buy | Option Exercise | 6,000 | $61K | 5/6/2022 | View on chart |
| OPCH | ▼ Sell | Open Market | 6,000 | $173K | 5/6/2022 | View on chart |
| OPCH | ▲ Buy | Option Exercise | 6,000 | $61K | 4/6/2022 | View on chart |
| OPCH | ▼ Sell | Open Market | 6,000 | $163K | 4/6/2022 | View on chart |
| OPCH | ▲ Buy | Option Exercise | 6,000 | $61K | 3/7/2022 | View on chart |
| OPCH | ▼ Sell | Open Market | 6,000 | $157K | 3/7/2022 | View on chart |
| OPCH | ▲ Buy | Option Exercise | 6,000 | $61K | 2/7/2022 | View on chart |
| OPCH | ▼ Sell | Open Market | 6,000 | $142K | 2/7/2022 | View on chart |
| OPCH | ▲ Buy | Option Exercise | 6,000 | $61K | 1/6/2022 | View on chart |
| OPCH | ▼ Sell | Open Market | 6,000 | $158K | 1/6/2022 | View on chart |
| OPCH | ▲ Buy | Option Exercise | 6,000 | — | 12/6/2021 | View on chart |
| OPCH | ▼ Sell | Open Market | 6,000 | $149K | 12/6/2021 | View on chart |
| OPCH | ▲ Buy | Option Exercise | 6,000 | — | 11/8/2021 | View on chart |
| OPCH | ▼ Sell | Open Market | 6,000 | $168K | 11/8/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
McKesson moves to acquire Option Care Health in $5.8B deal
Option Care Health is the target of a $5.8 billion acquisition by McKesson, which has lifted the stock in recent trading. The deal is under legal review, and several analysts have lowered their ratings, with UBS moving to neutral and William Blair to market‑perform. The mixed reactions reflect both the premium offered and the uncertainties around regulatory approval.
McKesson moves to acquire Option Care Health in $5.8B deal. Option Care Health is the target of a $5.8 billion acquisition by McKesson, which has lifted the stock in recent trading. The deal is under legal review, and several analysts have lowered their ratings, with UBS moving to neutral and William Blair to market‑perform. The mixed reactions reflect both the premium offered and the uncertainties around regulatory approval.